Fidelis Capital Partners LLC Boosts Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Fidelis Capital Partners LLC lifted its position in Amgen Inc. (NASDAQ:AMGN) by 26.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,569 shares of the medical research company’s stock after purchasing an additional 753 shares during the period. Fidelis Capital Partners LLC’s holdings in Amgen were worth $1,028,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC boosted its stake in shares of Amgen by 83,875.6% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock worth $1,980,571,000 after acquiring an additional 7,532,031 shares in the last quarter. Norges Bank acquired a new position in Amgen in the 4th quarter worth about $1,351,778,000. Price T Rowe Associates Inc. MD raised its holdings in Amgen by 158.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,950,013 shares of the medical research company’s stock worth $774,791,000 after purchasing an additional 1,806,456 shares during the period. International Assets Investment Management LLC purchased a new position in Amgen during the fourth quarter worth approximately $4,589,900,000. Finally, Morgan Stanley grew its holdings in Amgen by 12.9% in the fourth quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock valued at $3,493,471,000 after purchasing an additional 1,523,665 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on AMGN. Leerink Partnrs downgraded Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. StockNews.com downgraded shares of Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. Morgan Stanley dropped their target price on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 7th. Royal Bank of Canada restated an “outperform” rating and set a $329.00 price target on shares of Amgen in a research report on Wednesday, April 3rd. Finally, UBS Group lowered their price objective on Amgen from $314.00 to $284.00 and set a “neutral” rating on the stock in a report on Wednesday. Ten analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, Amgen presently has a consensus rating of “Moderate Buy” and an average price target of $296.95.

Amgen Trading Down 0.5 %

Shares of NASDAQ AMGN traded down $1.32 during trading on Thursday, hitting $262.75. 2,082,465 shares of the company were exchanged, compared to its average volume of 2,851,966. The company has a fifty day moving average price of $277.99 and a 200-day moving average price of $281.37. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The firm has a market capitalization of $140.81 billion, a PE ratio of 21.14, a P/E/G ratio of 2.47 and a beta of 0.58. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping the consensus estimate of $4.66 by $0.05. The company had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same period in the prior year, the business posted $4.09 earnings per share. As a group, equities research analysts expect that Amgen Inc. will post 19.46 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.43%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is presently 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.